Presentation is loading. Please wait.

Presentation is loading. Please wait.

Intranasal Glucagon Investigators

Similar presentations


Presentation on theme: "Intranasal Glucagon Investigators"— Presentation transcript:

1 Intranasal Glucagon Investigators
Intranasal Glucagon for Treatment of Insulin-Induced Hypoglycemia in Adults With Type 1 Diabetes: A Randomized Crossover Noninferiority Study Featured Article: Michael R. Rickels, Katrina J. Ruedy, Nicole C. Foster, Claude A. Piché, Hélène Dulude, Jennifer L. Sherr, William V. Tamborlane, Kathleen E. Bethin, Linda A. DiMeglio, R. Paul Wadwa, Andrew J. Ahmann, Michael J. Haller, Brandon M. Nathan, Santica M. Marcovina, Emmanouil Rampakakis, Linyan Meng, and Roy W. Beck, for the T1D Exchange Intranasal Glucagon Investigators Diabetes Care Volume 39: 264–270 February 2016

2 STUDY OBJECTIVE To compare a needle-free intranasal glucagon preparation with intramuscular glucagon for treatment of insulin-induced hypoglycemia Rickels M.R. et al. Diabetes Care 2016;39:264–270

3 STUDY DESIGN AND METHODS
Randomized crossover noninferiority trial was conducted Study included 75 adults with type 1 diabetes and compared intranasal versus intramuscular glucagon for treatment of hypoglycemia induced by intravenous insulin Success was defined as an increase in plasma glucose to ≥70 or ≥20 mg/dL from the glucose nadir within 30 min after receiving glucagon Rickels M.R. et al. Diabetes Care 2016;39:264–270

4 RESULTS Mean plasma glucose at time of glucagon administration was 48 ± 8 and 49 ± 8 mg/dL at the intranasal and intramuscular visits, respectively Success criteria were met at all but one intranasal visit and at all intramuscular visits Mean time to success was 16 min for intranasal and 13 min for intramuscular Head/facial discomfort was reported during 25% of intranasal and 9% of intramuscular dosing visits; nausea occurred with 35% and 38% of visits, respectively Rickels M.R. et al. Diabetes Care 2016;39:264–270

5 Rickels M.R. et al. Diabetes Care 2016;39:264–270

6 Rickels M.R. et al. Diabetes Care 2016;39:264–270

7 Rickels M.R. et al. Diabetes Care 2016;39:264–270

8 Rickels M.R. et al. Diabetes Care 2016;39:264–270

9 CONCLUSIONS Intranasal glucagon was highly effective in treating insulin-induced hypoglycemia in adults with type 1 diabetes Rickels M.R. et al. Diabetes Care 2016;39:264–270


Download ppt "Intranasal Glucagon Investigators"

Similar presentations


Ads by Google